Last Updated : October 26, 2023
Details
Generic Name:
pembrolizumab
Project Status:
Pending
Therapeutic Area:
Biliary tract carcinoma
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0344-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC), in combination with chemotherapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC), in combination with chemotherapy.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : October 26, 2023